Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Highly sensitive and specific plasma biomarkers for Alzheimer’s disease (AD) have the potential to improve diagnostic accuracy in the clinic and facilitate research studies including enrollment in prevention and treatment trials. We recently reported CSF tau hyperphosphorylation, especially on T217, is an accurate predictor of β-amyloidosis at asymptomatic and symptomatic stages. In the current study, we determine by mass spectrometry the potential utility of plasma p-tau isoforms to detect AD pathology and investigate CSF and plasma tau isoforms’ profile relationships. Plasma tau was truncated as previously described in CSF. CSF and plasma measures of p-tau-217 and p-tau-181 were correlated. No correlation was found between CSF and plasma on total-tau levels and pS202 measures. We found p-tau-217 and p-tau-181 were highly specific for amyloid plaque pathology in the discovery cohort (n = 36, AUROC = 0.99 and 0.98 respectively). In the validation cohort (n = 92), p-tau-217 measures were still specific to amyloid status (AUROC = 0.92), and p-tau-181 measures were less specific (AUROC = 0.75).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma tau measurement could thus be used as a screening test in early-stage clinical trials to enrich trial participation with individuals more likely to have AD pathology (76, 77, 90).”
From All the Tau We Cannot See (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Like NfL (neurofilament light chain), plasma tau has emerged as a marker of neuronal distress. It appears in several different neurodegenerative diseases, including importantly even preclinical AD patients (76–85).”
From All the Tau We Cannot See (2023) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma levels of p-tau are strongly associated with PET and CSF biomarkers of AD pathology19–25, neuropathological changes associated with AD20,23,26,27 and the subsequent development of AD dementia20,23,28.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CSF levels of Aβ and phosphorylated tau, as assessed by immunoassays, correlate with AD disease state and neurodegenerative pathology, but more disease specific information can be gleaned from assessment of the specific post-translational modifications of tau [37,59].”
From Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease (2025) · cites this paper as [37]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927
Self-citationRevisiting biomarker discovery by plasma proteomics
Geyer, P. E., Holdt, L. M., Teupser, D., & Mann, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20156297 · Cited by 917
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885 · cited 4×
“…biomarker compared with its measurement in CSF. Blood plasma amyloid-β (Aβ) 42/40 ratio recapitulates with accuracy change on Aβ42/40 ratio detected in CSF and associates with measures of brain amyloid plaques by amyloid PET scans (Ovod et al., 2017; Nakamura et al., 2018; Schindler et al., 2019).”
BackgroundMethodInfluentialSelf-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Self-citationMielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D. C., Knopman, D. S., Roberts, R. O., Machulda, M. M., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.013 · Cited by 621
Cited by
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
“42,53 Findings of a large, multi centre cohort study showed that plasma pTau217 can differentiate Alzheimer’s disease from non-Alzheimer’s disease dementias with high accuracy (96%), similar to the performance of established CSF or tau-PET biomarkers.”
InfluentialPost-Stroke Cognitive Impairment and Dementia
Rost, N. S., Brodtmann, A., Pase, M. P., van Veluw, S. J., Biffi, A., Duering, M., Hinman, J. D., & Dichgans, M. (2022) · Circulation Research · doi:10.1161/circresaha.122.319951 · Cited by 790
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021
Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N., & Rubino, I. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.23 · Cited by 744
“At present, only a limited number of approved blood-based assays are available to clinicians to detect AD pathology (88); however, several novel assays are currently under investigation, including those measuring various phosphorylated forms of tau, including p-tau181 and p-tau217 (89).”
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology.
Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Snellman, A., Schöll, M., Troakes, C., Hye, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02275-6 · Cited by 719
Alzheimer’s disease drug development pipeline: 2022
Cummings, J., Lee, G., Nahed, P., Kambar, M. E. Z. N., Zhong, K., Fonseca, J., & Taghva, K. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12295 · Cited by 665
“4 Nearly all the participants meeting the tau PET criteria had positive amyloid imaging; the discordance was 0.9% of individuals who met the tau PET criteria and not the amyloid PETcriteria.”
MethodInfluentialThijssen, E. H., La Joie, R., Strom, A., Fonseca, C., Iaccarino, L., Wolf, A., Spina, S., Allen, I. E., Cobigo, Y., Heuer, H., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00214-3 · Cited by 607
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557
Palmqvist, S., Tideman, P., Cullen, N., Zetterberg, H., Blennow, K., Initiative, T. A. D. N., Dage, J. L., Stomrud, E., Janelidze, S., Mattsson-Carlgren, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01348-z · Cited by 524
“Although there has been great progress recently in validating plasma P-tau as a biomarker for AD 14–16, 26– 30 and for individualized individualized prediction of cognitive decline in individuals classified as having MCI 17 , this paper is, to our knowledge, the first to present how plasma P-tau…”
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., et al. (2023) · Brain · doi:10.1093/brain/awac333 · Cited by 522
“7 The higher performance of p-tau217 over p-tau181 has been shown for immunoassays-based p-tau measures 10,12,13 as well as for CSF p-tau217 and p-tau181 34,35 and could be due to the specificity of p-tau217 for Alzheimer’s disease (this biomarker is found at considerably lower levels in people…”
Self-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer’s disease.
Forner, S., Kawauchi, S., Balderrama-Gutierrez, G., Kramár, E. A., Matheos, D. P., Phan, J., Javonillo, D. I., Tran, K. M., Hingco, E., da Cunha, C., et al. (2021) · Scientific Data · doi:10.1038/s41597-021-01054-y · Cited by 501
Performance of plasma phosphorylated tau 181 and 217 in the community
Mielke, M. M., Dage, J. L., Frank, R. D., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V. J., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01822-2 · Cited by 465
A current view on Tau protein phosphorylation in Alzheimer's disease
Wegmann, S., Biernat, J., & Mandelkow, E. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.03.003 · Cited by 456
Barthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02869-z · Cited by 448
“Plasma levels of p-tau are strongly associated with PET and CSF biomarkers of AD pathology 19–25 , neuropathological changes associated with AD 20,23,26,27 and the subsequent development of AD dementia 20,23,28 .”
BackgroundSelf-citationAshton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02074-w · Cited by 436
“Other p-tau217 assays may have more sensitive performance at the earliest changes of Aβ-PET 34 .”
Self-citationSuárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012921 · Cited by 401
“Importantly, that difference was replicated in a validation cohort that also comprised prodromal AD and CU individuals who were Ab-positive (Barthélemy et al, 2020a).”
BackgroundResultInfluentialEmerging diagnostics and therapeutics for Alzheimer disease
Self, W. K., & Holtzman, D. M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02505-2 · Cited by 381
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Karikari, T. K., Ashton, N. J., Brinkmalm, G., Brum, W. S., Benedet, A. L., Montoliu-Gaya, L., Lantero-Rodriguez, J., Pascoal, T. A., Suárez-Calvet, M., Rosa-Neto, P., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00665-2 · Cited by 329
Developing the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H., Cummings, J., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 327
Tauopathies: new perspectives and challenges
Zhang, Y., Wu, K.-M., Yang, L., Dong, Q., & Yu, J.-T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00533-z · Cited by 323
Moscoso, A., Grothe, M. J., Ashton, N. J., Karikari, T. K., Lantero Rodríguez, J., Snellman, A., Suárez-Calvet, M., Blennow, K., Zetterberg, H., Schöll, M., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4986 · Cited by 310
Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration
Ishida, K., Yamada, K., Nishiyama, R., Hashimoto, T., Nishida, I., Abe, Y., Yasui, M., & Iwatsubo, T. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20211275 · Cited by 298
“Our finding that an impairment in clearance led to the significant elevation of CSF tau suggests that tau levels in CSF are more dynamically regulated than previously conceptualized (Barth´elemy et al., 2020b).”
Emerging roles of innate and adaptive immunity in Alzheimer’s disease
Chen, X., & Holtzman, D. M. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.016 · Cited by 297
Schindler, S. E., Galasko, D., Pereira, A. C., Rabinovici, G. D., Salloway, S., Suárez-Calvet, M., Khachaturian, A. S., Mielke, M. M., Udeh-Momoh, C., Weiss, J., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00977-5 · Cited by 290
“In particular, assays of plasma levels of p-tau217 or the ratio of p-tau217 to non-phosphorylated tau have AUCs of 0.92–0.98, which is similar to those of CSF tests for classifying amyloid PET status 48,58–61 .”
InfluentialHampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.017 · Cited by 283
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
Mattsson‐Carlgren, N., Janelidze, S., Bateman, R. J., Smith, R., Stomrud, E., Serrano, G. E., Reiman, E. M., Palmqvist, S., Dage, J. L., Beach, T. G., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114022 · Cited by 261
Self-citationProteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery
Bai, B., Vanderwall, D., Li, Y., Wang, X., Poudel, S., Wang, H., Dey, K. K., Chen, P.-C., Yang, K., & Peng, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00474-z · Cited by 257
“Although the pTau analysis is promising, its concentration in blood is extremely low (< 1 pg/ml) [211], requiring antibody-affinity enrichment, or highly sensitive”
BackgroundBrain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration
Gonzalez-Ortiz, F., Turton, M., Kac, P. R., Smirnov, D., Premi, E., Ghidoni, R., Benussi, L., Cantoni, V., Saraceno, C., Rivolta, J., et al. (2023) · Brain · doi:10.1093/brain/awac407 · Cited by 252
“25,27,29 Furthermore, BD-tau in blood, like NfL, has high diagnostic accuracy to detect neurodegeneration in Alzheimer ’ s disease.”
InfluentialCSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02443-z · Cited by 249
Self-citationMielke, M. M., Frank, R. D., Dage, J. L., Jeromin, A., Ashton, N. J., Blennow, K., Karikari, T. K., Vanmechelen, E., Zetterberg, H., Algeciras-Schimnich, A., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.2293 · Cited by 244
Tolar, M., Hey, J., Power, A., & Abushakra, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126355 · Cited by 243
“Plasma assays for p-tau181, and more recently p-tau217, are being developed and may provide a convenient blood-based biomarker to evaluate longitudinal changes and drug efficacy in future AD trials [62,63].”
BackgroundDiagnostic and prognostic plasma biomarkers for preclinical Alzheimer’s disease
Chatterjee, P., Pedrini, S., Ashton, N. J., Tegg, M., Goozee, K., Singh, A. K., Karikari, T. K., Simrén, J., Vanmechelen, E., Armstrong, N. J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12447 · Cited by 231
Ashton, N. J., Puig‐Pijoan, A., Milà‐Alomà, M., Fernández‐Lebrero, A., García‐Escobar, G., González‐Ortiz, F., Kac, P. R., Brum, W. S., Benedet, A. L., Lantero‐Rodriguez, J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12841 · Cited by 230
Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum
Moscoso, A., Grothe, M. J., Ashton, N. J., Karikari, T. K., Rodriguez, J. L., Snellman, A., Suárez-Calvet, M., Zetterberg, H., Blennow, K., Schöll, M., et al. (2021) · Brain · doi:10.1093/brain/awaa399 · Cited by 229
“In addition, two recent studies suggested highly promising diagnostic performance for plasma-derived tau phosphorylated at threonine 217 (Barthelemy et al., 2020; Palmqvist et al., 2020).”
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Zetterberg, H., & Blennow, K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00430-x · Cited by 219
Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS
(2024) · doi:10.1038/s41591-024-02937-4 · Cited by 217
Self-citationPlasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Gonzalez-Ortiz, F., Kac, P. R., Brum, W. S., Zetterberg, H., Blennow, K., & Karikari, T. K. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00605-8 · Cited by 214
Mouse Models of Alzheimer’s Disease
Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.912995 · Cited by 213
“Some phosphorylation sites of tau (threonine residues at 181, 217, and 231) are specifically phosphorylated in AD patients, and CSF and plasma tau are useful biomarkers of AD pathology (Barthélemy et al., 2020; Janelidze et al., 2020).”
BackgroundSystematic Phenotyping and Characterization of the 3xTg-AD Mouse Model of Alzheimer’s Disease
Javonillo, D. I., Tran, K. M., Phan, J., Hingco, E., Kramár, E. A., da Cunha, C., Forner, S., Kawauchi, S., Milinkeviciute, G., Gomez-Arboledas, A., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.785276 · Cited by 203
Pais, M. V., Forlenza, O. V., & Diniz, B. S. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-230029 · Cited by 156
Designing the next-generation clinical care pathway for Alzheimer’s disease
Hampel, H., Au, R., Mattke, S., van der Flier, W. M., Aisen, P., Apostolova, L., Chen, C., Cho, M., De Santi, S., Gao, P., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00269-x · Cited by 191
Bayoumy, S., Verberk, I. M. W., den Dulk, B., Hussainali, Z., Zwan, M., van der Flier, W. M., Ashton, N. J., Zetterberg, H., Blennow, K., Vanbrabant, J., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00939-9 · Cited by 190
“Recently, using a mass spectrometry approach that simultaneously quantifies different P-tau forms, the different phosphorylation sites that are quantified in this study were not phosphorylated to the same degree, with phosphorylation of P-tau181 present to a high degree in plasma and CSF of controls and with a relativ…”
BackgroundJanelidze, S., Barthélemy, N. R., He, Y., Bateman, R. J., & Hansson, O. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.0199 · Cited by 176
Self-citationEquivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease
Therriault, J., Servaes, S., Tissot, C., Rahmouni, N., Ashton, N. J., Benedet, A. L., Karikari, T. K., Macedo, A. C., Lussier, F. Z., Stevenson, J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13026 · Cited by 172
“Amyloid-β SUVR from a neocortical region of interest (ROI) for each participant was estimated by averaging the SUVR from the precuneus, prefrontal, orbitofrontal, parietal, temporal, and cingulate cortices, 32 with amyloid-β positivity defined as an [ 18 F]AZD4694 above 1.55.”
BackgroundMethodInfluentialA comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests
Warmenhoven, N., Salvadó, G., Janelidze, S., Mattsson, N., Bali, D., Dolado, A. O., Kolb, H. C., Triana‐Baltzer, G., Barthélemy, N. R., Schindler, S. E., et al. (2024) · Brain · doi:10.1093/brain/awae346 · Cited by 166
Self-citationChallenges in the practical implementation of blood biomarkers for Alzheimer’s disease
Schöll, M., Verberk, I. M. W., del Campo, M., Delaby, C., Therriault, J., Chong, J. R., Palmqvist, S., & Alcolea, D. A. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.07.013 · Cited by 162
“20 p-tau217:best-performingbloodbiomarkerdue togreatestdynamic range 21 andsensitivity.”
Rissman, R. A., Langford, O., Raman, R., Donohue, M. C., Abdel‐Latif, S., Meyer, M. R., Wente‐Roth, T., Kirmess, K. M., Ngolab, J., Winston, C. N., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13542 · Cited by 157
“16 Although no relationship was observed for total tau, significantcorrelationswerefound betweenCSFand plasmap-tau181 and p-tau217 concentrations.”
BackgroundBlood–brain barrier link to human cognitive impairment and Alzheimer’s disease
Barisano, G., Montagne, A., Kisler, K., Schneider, J. A., Wardlaw, J. M., & Zlokovic, B. V. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-021-00014-4 · Cited by 157
Barthélemy, N. R., Saef, B., Li, Y., Gordon, B. A., He, Y., Horie, K., Stomrud, E., Salvadó, G., Janelidze, S., Sato, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00380-7 · Cited by 153
Self-citationSchindler, S. E., Karikari, T. K., Ashton, N. J., Henson, R. L., Yarasheski, K. E., West, T., Meyer, M. R., Kirmess, K. M., Li, Y., Saef, B., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200358 · Cited by 141
Self-citationJanelidze, S., Barthélemy, N. R., Salvadó, G., Schindler, S. E., Palmqvist, S., Mattsson, N., Braunstein, J. B., Ovod, V., Bollinger, J. G., He, Y., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.2619 · Cited by 144
Self-citationAshton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05253-y · Cited by 142
“The usefulness of plasma p-tau217 was supported by a recent mass spectrometrybased study [99].”
BackgroundMeyer, M. R., Kirmess, K. M., Eastwood, S., Wente‐Roth, T. L., Irvin, F., Holubasch, M. S., Venkatesh, V., Fogelman, I., Monane, M., Hanna, L., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13764 · Cited by 121
Self-citationAshton, N. J., Suárez‐Calvet, M., Karikari, T. K., Lantero‐Rodriguez, J., Snellman, A., Sauer, M., Simrén, J., Minguillon, C., Fauria, K., Blennow, K., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12168 · Cited by 121
Angioni, D., Delrieu, J., Hansson, O., Fillit, H., Aisen, P., Cummings, J., Sims, J. R., Braunstein, J. B., Sabbagh, M., Bittner, T., et al. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.85 · Cited by 126
Self-citationPlasma phosphorylated tau 217 in preclinical Alzheimer’s disease
Jonaitis, E. M., Janelidze, S., Cody, K. A., Langhough, R., Du, L., Chin, N. A., Mattsson-Carlgren, N., Hogan, K. J., Christian, B. T., Betthauser, T. J., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad057 · Cited by 124
“18,25,26 Here we report a study from the Wisconsin Registry for Alzheimer’s Prevention (WRAP) 27 in which we examine plasma pTau 217 trajectories in CU adults using Lilly’s immunoassay for the Meso Scale Discovery platform (Lilly-MSD).”
Montoliu-Gaya, L., Benedet, A. L., Tissot, C., Vrillon, A., Ashton, N. J., Brum, W. S., Lantero-Rodriguez, J., Stevenson, J., Nilsson, J., Sauer, M., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00405-1 · Cited by 122
Cano, A., Turowski, P., Ettcheto, M., Duskey, J. T., Tosi, G., Sánchez-López, E., García, M. L., Camins, A., Souto, E. B., Ruiz, A., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00864-x · Cited by 122
(2020) · Brain · doi:10.1093/brain/awaa403 · Cited by 103
“A mass spectrometry-based plasma p-tau217 assay (Barthélemy et al., 2020) has also shown good predictive capacity for CSF amyloid status in two smaller cohorts consisting of a mixture of younger and older controls, and individuals with cognitive impairment with and without CSF amyloid pathology…”
MethodNew Frontiers in the Prevention, Diagnosis, and Treatment of Alzheimer’s Disease
Guzmán‐Martínez, L., Calfío, C., Farias, G. A., Vilches, C., Prieto, R., & Maccioni, R. B. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201059 · Cited by 120
Mendes, A. J., Ribaldi, F., Lathuilière, A., Ashton, N. J., Janelidze, S., Zetterberg, H., Scheffler, M., Assal, F., Garibotto, V., Blennow, K., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-023-12148-5 · Cited by 120
“Thus, our findings confirm previous studies suggesting that plasma p -tau217 is more effective in detecting AD pathology than p -tau181 [13, 16, 33–35] and p -tau231 [17, 21].”
Chong, J. R., Ashton, N. J., Karikari, T. K., Tanaka, T., Schöll, M., Zetterberg, H., Blennow, K., Chen, C., & Lai, M. K. P. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327370 · Cited by 115
“47”
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
Kim, A. Y., Jerdi, S. A., MacDonald, R., & Triggle, C. R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1399121 · Cited by 116
Stocker, H., Beyer, L., Perna, L., Rujescu, D., Holleczek, B., Beyreuther, K., Stockmann, J., Schöttker, B., Gerwert, K., & Brenner, H. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12614 · Cited by 98
Ashton, N. J., Keshavan, A., Brum, W. S., Andréasson, U., Arslan, B., Droescher, M., Barghorn, S., Vanbrabant, J., Lambrechts, C., Loo, M. V., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14508 · Cited by 108
“Since the initial studies piloting p-tau detection in blood, 25,26 and immunoprecipitation mass spectrometry [IPMS] 14,32 ).”
Janigro, D., Bailey, D. M., Lehmann, S., Badaut, J., O’flynn, R., Hirtz, C., & Marchi, N. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.577312 · Cited by 105
Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
Thijssen, E. H., Verberk, I. M. W., Kindermans, J., Abramian, A., Vanbrabant, J., Ball, A. J., Pijnenburg, Y., Lemstra, A. W., van der Flier, W. M., Stoops, E., et al. (2022) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12285 · Cited by 86
CSF tau microtubule-binding region identifies pathological changes in primary tauopathies
Horie, K., Barthélemy, N. R., Spina, S., VandeVrede, L., He, Y., Paterson, R. W., Wright, B. A., Day, G. S., Davis, A. A., Karch, C. M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02075-9 · Cited by 97
Self-citationGleason, C. E., Zuelsdorff, M., Gooding, D. C., Kind, A. J. H., Johnson, A. L., James, T. T., Lambrou, N. H., Wyman, M. F., Ketchum, F. B., Gee, A., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12511 · Cited by 104
Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
González‐Ortiz, F., Kirsebom, B., Contador, J., Tanley, J. E., Selnes, P., Gísladóttir, B., Pålhaugen, L., Hemminghyth, M. S., Jarholm, J. A., Skogseth, R. E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47286-5 · Cited by 103
Plasma p‐tau immunoassays in clinical research for Alzheimer's disease
Teunissen, C. E., Kolster, R., Triana‐Baltzer, G., Janelidze, S., Zetterberg, H., & Kolb, H. C. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14397 · Cited by 103
“A study by Barthelemy et al. 34 also showed that the reduction in the p-tau217/tau217 ratio from CSF to plasma is smaller than the reductionobservedforp-tau181/tau181,whichtheauthorssuggested might reflect less dilution by unphosphorylated peripheral tau contribution for p-tau217 compared to…”
InfluentialGroot, C., Cicognola, C., Bali, D., Triana-Baltzer, G., Dage, J. L., Pontecorvo, M. J., Kolb, H. C., Ossenkoppele, R., Janelidze, S., & Hansson, O. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01005-8 · Cited by 99
Plasma biomarkers predict Alzheimer’s disease before clinical onset in Chinese cohorts
Cai, H., Pang, Y., Fu, X., Ren, Z., & Jia, L. (2023) · Nature Communications · doi:10.1038/s41467-023-42596-6 · Cited by 101
“Source data are provided as a Source Data fi le. studies 47,48 have revealed that tau in CSF comprises N-terminal and mid-region species, while in blood, it predominantly exists in N-terminal forms.”
Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review
Leipp, F., Vialaret, J., Mohaupt, P., Coppens, S., Jaffuel, A., Niehoff, A., Lehmann, S., & Hirtz, C. (2024) · Brain Communications · doi:10.1093/braincomms/fcae396 · Cited by 101
Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset
Li, Y., Yen, D., Hendrix, R. D., Gordon, B. A., Dlamini, S., Barthélemy, N. R., Aschenbrenner, A. J., Henson, R. L., Herries, E. M., Volluz, K., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26891 · Cited by 87
“12,14 In contrast, CSF pT205/T205 is well correlated with tau PET but relatively poorly correlated with amyloid PET, 12,15 making it a more speci fi c bio-marker of tau pathology.”
BackgroundSelf-citationAbu‐Rumeileh, S., Scholle, L. M., Mensch, A., Großkopf, H., Ratti, A., Kölsch, A., Stoltenburg, G., Conrad, J., Gobbi, A. D., Barba, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57144-7 · Cited by 96
“Notably, p-tau 181 and p-tau 217 have been proposed as “ more CNS speci fi c tau species ” in blood than t-tau and other p-tau species, such as p-tau 202 17 .”
Current directions in tau research: Highlights from Tau 2020
Sexton, C., Snyder, H., Beher, D., Boxer, A. L., Brannelly, P., Brion, J., Buée, L., Cacace, A. M., Chételat, G., Citron, M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12452 · Cited by 79
Acute sleep loss decreases CSF‐to‐blood clearance of Alzheimer's disease biomarkers
Liu, H., Barthélemy, N. R., Ovod, V., Bollinger, J. G., He, Y., Chahin, S. L., Androff, B., Bateman, R. J., & Lucey, B. P. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.12930 · Cited by 93
Self-citationZeng, X., Chen, Y., Sehrawat, A., Lee, J., Lafferty, T. K., Kofler, J., Berman, S., Sweet, R. A., Tudorascu, D. L., Klunk, W. E., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00711-1 · Cited by 94
Tosun, D., Veitch, D., Aisen, P., Jack, C. R., Jagust, W. J., Petersen, R. C., Saykin, A. J., Bollinger, J., Ovod, V., Mawuenyega, K. G., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab008 · Cited by 79
“Compared to the limited number of previously reported evaluations of plasma ptau181 as a biomarker of brain Ab-positivity in other research and clinical cohorts (Mielke et al., 2018; Palmqvist et al., 2019b; Barthélemy et al., 2020; Janelidze et al., 2020a; Karikari et al., 2020; Thijssen et al., 2020), ADNI plasma p-…”
BackgroundMethodInfluentialSelf-citationThe informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
Self-citationP-tau217 as a Reliable Blood-Based Marker of Alzheimer’s Disease
Lai, R., Li, B., & Bishnoi, R. J. (2024) · Biomedicines · doi:10.3390/biomedicines12081836 · Cited by 88
Alzheimer’s disease biomarkers and their current use in clinical research and practice
Hunter, T., Santos, L. E., Tovar-Moll, F. F., & Felice, F. G. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02709-z · Cited by 88
“Since the majority of plasma total-tau originates from peripheral sources, higher CNS t-tau in AD is unlikely to cause signi fi cant increases in plasma t-tau [105].”
Korecka, M., & Shaw, L. M. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15465 · Cited by 88
“…more sensitively detect both the pre- clinical and advanced forms of AD (Barthelemy et al., 2020), although the same group have reported closely parallel performance of p- tau217 and increases in p- tau181 for detection of both the pre- clinical and advanced forms of AD (Barthelemy et al., 2020).”
BackgroundInfluentialBiomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 89
Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations
Bornhorst, J. A., Lundgreen, C. S., Weigand, S. D., Figdore, D. J., Wiste, H. J., Griswold, M. E., Vemuri, P., Graff‐Radford, J., Knopman, D. S., Cogswell, P., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000210287 · Cited by 84
Beyer, L., Stocker, H., Rujescu, D., Holleczek, B., Stockmann, J., Nabers, A., Brenner, H., & Gerwert, K. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12745 · Cited by 81
Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases
Schuh, A. F. S., Bieger, A., Borelli, W. V., Portley, M. K., Awad, P. S., & Bandrés‐Ciga, S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.792227 · Cited by 80
Brain Structural and Functional Changes in Cognitive Impairment Due to Alzheimer’s Disease
Ávila‐Villanueva, M., Dolado, A. M., Gómez‐Ramírez, J., & Fernández‐Blázquez, M. A. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.886619 · Cited by 79
“In order to do that, we need earlier markers that could be obtained from liquid samples [blood or cerebrospinal fluid (CSF)] (Barthélemy et al., 2020) or image analysis like PET (Vlasenko et al.”
BackgroundUllah, R., Park, T. J., Huang, X., & Kim, M. O. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101451 · Cited by 78
“…two recent studies also showed highly promising diagnostic performance for plasma pTau, especially p-tau-217, which can differentiate AD patients from controls and non-AD dementia with high accuracy, and can therefore predict clinical progression (Barthelemy et al., 2020; Palmqvist et al., 2020).”
Kametani, F., Yoshida, M., Matsubara, T., Murayama, S., Saito, Y., Kawakami, I., Onaya, M., Tanaka, H., Kakita, A., Robinson, A. C., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.581936 · Cited by 76
“Phosphorylation of 217Thr has recently been reported to be a biomarker of AD (Barthelemy et al., 2020; Janelidze et al., 2020; Palmqvist et al., 2020).”
Backgroundd’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 78
Xiao, Z., Wu, X. Y., Wu, W., Yi, J., Liang, X., Ding, S., Zheng, L., Luo, J., Gu, H., Zhao, Q., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00864-x · Cited by 76
“58 Following Aβ1-42, Aβ1-40, total tau (t-tau), neurofilament protein light chain (NfL), 59 recently reported plasma phosphorylated tau at threonine 181 (p-tau181) showed 60 better diagnostic performance and prognostic value in several cohort studies [3-9].”
BackgroundDiagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
Kac, P. R., Gonzalez-Ortiz, F., Simrén, J., Dewit, N., Vanmechelen, E., Zetterberg, H., Blennow, K., Ashton, N. J., & Karikari, T. K. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01011-w · Cited by 73
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
Triana‐Baltzer, G., Moughadam, S., Slemmon, R., Van Kolen, K., Theunis, C., Mercken, M., & Kolb, H. C. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12204 · Cited by 64
Yamada, K., & Iwatsubo, T. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05225-z · Cited by 70
“Recent advances in highly sensitive mass spectrometry and immunoassays have made it possible to reliably measure Aβ and tau levels in the blood, providing promising, less-invasive indicators of AD brain pathology [76 , 77 ].”
BackgroundBiofluid Biomarkers of Alzheimer’s Disease: Progress, Problems, and Perspectives
Huang, S., Wang, Y., & Guo, J. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00836-7 · Cited by 67
“67), and whether these outcomes are reliable deserve further investigation [60, 78].”
BackgroundA Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
Coomans, E. M., Verberk, I. M. W., Ossenkoppele, R., Verfaillie, S. C. J., Visser, D., Gouda, M., Tuncel, H., Wolters, E. E., Timmers, T., Windhorst, A. D., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264279 · Cited by 65
“Previous studies have suggested that plasma pTau217 might have slightly favorable properties compared to plasma pTau181 in terms of dynamic range(44), predicting Aβ status(10) and differentiating between clinical AD dementia and other neurodegenerative dementias(45).”
BackgroundShea, D. W., Colasurdo, E. A., Smith, A. S. T., Paschall, C. J., Jayadev, S., Keene, C. D., Galasko, D. R., Ko, A. L., Li, G., Peskind, E. R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2213157119 · Cited by 65
Kang, J. H., Korecka, M., Lee, E. B., Cousins, K. A. Q., Tropea, T. F., Chen-Plotkin, A. A., Irwin, D. J., Wolk, D., Brylska, M., Wan, Y., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad139 · Cited by 64
Metadata
- Authors
- Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Barthélemy, Nicolas R.
- Bateman, Randall J.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-07-28
- Volume
- 217
- Issue
- 11
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7596823
- OpenAlex
- W3045987239
- Cited by
- 437
- References
- 36
- Citations by year
- 2026: 57 · 2025: 72 · 2024: 72 · 2023: 64 · 2022: 82 · 2021: 71 · 2020: 19
- FWCI
- 35.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
- Funders
- Alzheimer’s Association (AARF-16-443265)
- Rainwater Charitable Foundation
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke (R01NS095773)
- Tau SILK Consortium
- AbbVie
- Biogen
- Eli Lilly and Company
- Coins for Alzheimer’s Research Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau isoforms, CSF tau, plasma biomarkers, amyloid plaques, beta-amyloidosis, diagnostic accuracy, tau truncation
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Male, Middle Aged, Phosphorylation, Mass Spectrometry, Cohort Studies, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Protein Isoforms, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.